ArticleInflammopharmacology2025
Stabilizing effect of green tea extract and epigallocatechin-3-gallate (EGCG) on mast cell : an in vivo study.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mast cells are vital participants in the pathophysiology of allergic reactions by a process of degranulation where bioactive mediators such as histamine, leukotrienes, interleukins and prostaglandins are released to create the local inflammatory milieu. These mediators play an important role in the onset and advancements of allergic diseases, causing bronchoconstriction, as well as increased vascular permeability and local tissue inflammation. Stabilisation of mast cells is one of the essential therapeutic approaches to prevent excessive degranulation and consequent inflammatory aftermaths in allergic conditions. A major polyphenolic component of green tea, epigallocatechin gallate (EGCG), has been postulated to have mast cell-stabilising effects due to its antioxidant and anti-inflammatory effects. It has been reported that EGCG modulates immune responses through inhibition of oxidative stress and control of proinflammatory cytokines secretion. Due to its natural origin and excellent safety profile, EGCG emerges as an alternative treatment for allergic diseases in comparison to the traditional anti-allergic pharmacotherapy such as antihistamines and corticosteroids which have adverse effects long-term usage. In the present study, in vivo anti-allergic activity of EGCG was assessed using bovine serum albumin (BSA)-induced allergy model in male Brown Norway rats. Different levels of EGCG were administered to the experimental groups, while markers of allergic responses were investigated including the histamine concentration and cytokine profiles. The administration of EGCG led to a dose-dependent inhibition of proinflammatory cytokines and histamine concentrations, which implies strong suppression of degranulation of mast cells. These findings indicate that EGCG has therapeutic promise in addressing the mast cell-based allergic diseases.
Indexed as
Identifiers
40533674What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.